glp-1 news september 2025 30 Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and GLP-1 Weight-Loss Drug Demonstration Begins

In intrauterine adhesion models, semaglutide demonstrated anti-fibrotic properties, inhibiting epithelial-mesenchymal transition (the process by which epithelial cells transform into fibrotic, scar-like tissue)

Beneficial Consequences of GLP-1RA Effects on Gastric Emptying Reduction in Postmeal Glycemic Excursions Elevation of postprandial glycemia (PPG) is characteristically the initial defect in glucose intolerance (1) and is a challenging aspect of the management of T2D (2)

ArakawaMMitaTAzumaKEbatoCGotoHNomiyamaTet alInhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4

To reduce the potential bias related to heterogeneous baseline illnesses across the recruited RCTs, we arranged subgroup analysis focusing on those RCTs recruiting subjects with a baseline illness of diabetes, which was the major indication of GLP-1 receptor agonists and SGLT2 inhibitors